Oramed Pharmaceuticals Stock Current Ratio
| ORMP Stock | USD 2.37 0.02 0.85% |
Oramed Pharmaceuticals fundamentals help investors to digest information that contributes to Oramed Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Oramed Stock. The fundamental analysis module provides a way to measure Oramed Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oramed Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 24.61 | 25.84 |
Oramed | Current Ratio |
Oramed Pharmaceuticals Company Current Ratio Analysis
Oramed Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Oramed Pharmaceuticals Current Ratio | 21.01 X |
Most of Oramed Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oramed Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Oramed Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Oramed Pharmaceuticals is extremely important. It helps to project a fair market value of Oramed Stock properly, considering its historical fundamentals such as Current Ratio. Since Oramed Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oramed Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oramed Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Oramed Current Ratio Historical Pattern
Today, most investors in Oramed Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Oramed Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Oramed Pharmaceuticals current ratio as a starting point in their analysis.
Oramed Pharmaceuticals Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Oramed Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Oramed Pharmaceuticals has a Current Ratio of 21.01 times. This is much higher than that of the Pharmaceuticals sector and 200.14% higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
Oramed Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oramed Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oramed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oramed Pharmaceuticals by comparing valuation metrics of similar companies.Oramed Pharmaceuticals is currently under evaluation in current ratio category among related companies.
Oramed Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Oramed Pharmaceuticals from analyzing Oramed Pharmaceuticals' financial statements. These drivers represent accounts that assess Oramed Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Oramed Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 57.9M | 71.7M | 560.3M | 469.1M | 422.2M | 443.3M | |
| Enterprise Value | 54.6M | 52.4M | 483.6M | 429.6M | 386.6M | 405.9M |
Oramed Fundamentals
| Return On Equity | 0.0324 | ||||
| Return On Asset | -0.0516 | ||||
| Profit Margin | 4.12 % | ||||
| Operating Margin | (11.77) % | ||||
| Current Valuation | (16.94 M) | ||||
| Shares Outstanding | 40.52 M | ||||
| Shares Owned By Insiders | 11.20 % | ||||
| Shares Owned By Institutions | 13.86 % | ||||
| Number Of Shares Shorted | 583.94 K | ||||
| Price To Earning | (11.22) X | ||||
| Price To Book | 0.62 X | ||||
| Price To Sales | 76.20 X | ||||
| Revenue | 2.7 M | ||||
| Gross Profit | 2.7 M | ||||
| EBITDA | (36.98 M) | ||||
| Net Income | (37.76 M) | ||||
| Cash And Equivalents | 133.91 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 894 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.01 X | ||||
| Book Value Per Share | 4.06 X | ||||
| Cash Flow From Operations | (27.92 M) | ||||
| Short Ratio | 3.95 X | ||||
| Earnings Per Share | 0.14 X | ||||
| Target Price | 4.25 | ||||
| Beta | 1.82 | ||||
| Market Capitalization | 95.22 M | ||||
| Total Asset | 161.64 M | ||||
| Retained Earnings | (163.08 M) | ||||
| Working Capital | 109.37 M | ||||
| Current Asset | 31 M | ||||
| Current Liabilities | 4 M | ||||
| Net Asset | 161.64 M |
About Oramed Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oramed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oramed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oramed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Oramed Pharmaceuticals Piotroski F Score and Oramed Pharmaceuticals Altman Z Score analysis. To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Oramed Stock analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Oramed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oramed Pharmaceuticals. If investors know Oramed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oramed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.14 | Revenue Per Share 0.033 | Quarterly Revenue Growth (1.00) | Return On Assets (0.05) | Return On Equity 0.0324 |
The market value of Oramed Pharmaceuticals is measured differently than its book value, which is the value of Oramed that is recorded on the company's balance sheet. Investors also form their own opinion of Oramed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oramed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oramed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oramed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oramed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oramed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.